Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Neuralstem Inc is a clinical-stage biopharmaceutical company. The company is engaged in research, development, and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. Its technology base has produced three p... Neuralstem Inc is a clinical-stage biopharmaceutical company. The company is engaged in research, development, and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. Its technology base has produced three primary assets: NSI-189 small molecule program, NSI-566 stem cell therapy program and novel and proprietary new chemical entity screening platform. Mehr anzeigen
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was...
Letter from Seneca Biopharma's Executive Chairman PR Newswire GERMANTOWN, Md., Sept. 2, 2020 GERMANTOWN, Md., Sept. 2, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a...
Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering PR Newswire GERMANTOWN, Md., May 27, 2020 GERMANTOWN, Md., May 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc...
Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA PR Newswire GERMANTOWN, Md., Oct. 31, 2019 GERMANTOWN, Md., Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a...
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases PR Newswire GERMANTOWN, Md., Oct. 30, 2019...
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit PR Newswire GERMANTOWN, Md., Oct. 28, 2019 GERMANTOWN, Md., Oct. 28, 2019 /PRNewswire/...
Neuralstem Becomes Seneca Biopharma PR Newswire GERMANTOWN, Md., Oct. 28, 2019 GERMANTOWN, Md., Oct. 28, 2019 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ:CUR), announces that the company has changed...
Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4) PR Newswire GERMANTOWN, Md., Oct. 3, 2019 GERMANTOWN, Md., Oct. 3, 2019 /PRNewswire/ -- Neuralstem, Inc...
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients PR Newswire GERMANTOWN, Md., Sept. 24, 2019 GERMANTOWN, Md...
Neuralstem Reports Second Quarter 2019 Fiscal Results PR Newswire GERMANTOWN, Md., Aug. 14, 2019 GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
